In this Psychedelic Podcast episode, Paul F. Austin welcomes Phoebe McPherson to discuss the resurgence of kanna, a legal psychoactive plant, in the global market.
Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-210-phoebe-mcpherson
Paul and Phoebe explore kanna’s rich South African history, heart-opening qualities, and recent revival in the wellness space. Their comprehensive discussion asks questions like: How does kanna compare to MDMA? What led Phoebe to explore kanna, and how did it change her life? How can this plant help regulate the nervous system? Can you stack kanna extract with psychedelics like psilocybin and LSD? What does a kanna microdosing protocol look like?
Paul and Phoebe uncover everything you need to know about starting a kanna protocol, safe product sourcing, and ingestion tips.
Phoebe McPherson:
Phoebe McPherson is an educator, herbalist, gatherer, and the Head of Brand & Education at Fungtion, a nature-inspired wellness brand on a mission to help people reconnect to their bodies and nature through mushroom and plant formulas. Phoebe has spent years working with and learning from experts in the field about the healing aspects of nature’s gifts. While she is deeply knowledgeable about medicinal mushrooms, psychedelics, and plants, her passion lies in sharing kanna (Sceletium tortuosum) with the world, helping others find safety in their first steps to connect with nature.
Highlights:
Key Links:
Episode Sponsors:
In this Psychedelic Podcast episode, Paul F. Austin welcomes Jonathan Sabbagh, CEO of Journey Clinical, who shares his mission to integrate FDA-approved psychedelics within the modern therapeutic framework.
Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-209-jonathan-sabbagh/
Jonathan highlights the disjointed nature of today’s mental health system, where therapists and prescribers lack communication, hindering comprehensive assessments and referrals. He and Paul emphasize Journey Clinical’s collaborative care model, streamlining information exchange, and maximizing psychedelic-therapy access through telemedicine innovation. They explore Journey’s potential challenges of scalability, therapist training, and insurance coverage for extended sessions. And they consider the balance between state-level decriminalization, psychedelic medicalization, and decentralized access.
Join Paul and Jonathan as they imagine a new mental healthcare infrastructure that addresses the growing crisis and reinvents therapeutic care as we know it.
Jonathan Sabbagh:
Jonathan Sabbagh is the Co-Founder and CEO of Journey Clinical, the leading telehealth platform expanding access to psychedelic-assisted psychotherapy. A serial entrepreneur, Jonathan built his career in finance, spending over two decades working for hedge funds and building businesses in Switzerland and NYC.
After receiving a difficult diagnosis of PTSD and extreme burnout, Jonathan left the world of finance to focus on his mental health. During that time, he personally experienced the transformative benefits of plant medicine and ketamine-assisted psychotherapy (KAP). Jonathan’s healing journey inspired him to begin formal clinical psychology training at the New School, with the vision of expanding access to transformative psychedelic-assisted therapies to the millions of Americans with depression and anxiety.
Jonathan’s personal and professional journey motivated him to found Journey Clinical in 2020, the #1 platform in the US that enables licensed mental health professionals to deliver KAP at scale.
Highlights:
Key Links:
Episode Sponsors:
In this Psychedelic Podcast episode, Paul F. Austin meets meditation teacher and healer Spring Washam at the MAPS Psychedelic Science Conference to discuss Buddhism, psychedelics, and ancestral wisdom.
Find episode links, summary, and transcript here: https://thethirdwave.co/podcast/episode-208-spring-washam
Paul and Spring delve deep into the synergies and incompatibilities across healing modalities. They ask whether indoor practices can ever rival nature’s transformative power. They reflect on innate desires toward rooting on land and the consequences of disconnection. They ask whether the spirit of Harriet Tubman and other ancestral heroes can heal society’s conflicts. And they explore the psychedelic divide between Southern traditions and Northern adaptations.
Join Paul and Spring for a fascinating perspective on mindfulness, plant medicine, and the evolution of society.
Spring Washam:
Considered a pioneer in bringing mindfulness-based meditation to diverse communities; Spring Washam is a well-known teacher, healer, and visionary leader based in Oakland, California.
She is the author of A Fierce Heart: Finding Strength, Courage and Wisdom in Any Moment and The Spirit of Harriet Tubman: Awakening from the Underground.
Spring is one of the founding teachers at the East Bay Meditation Center, an organization that offers Buddhist teachings with attention to social action and multiculturalism. She is a member of the teachers’ council at Spirit Rock Meditation Center, offering teachings on Buddhist philosophy, Insight meditation, and loving-kindness practices. Spring is also the founder of Lotus Vine Journeys, a one-of-a-kind organization that blends indigenous healing practices with Buddhist wisdom in transformative retreats in Central America.
She has practiced and studied Buddhist philosophy in both the Theravada and Tibetan schools of Buddhism since 1999. Spring is also a shamanic practitioner, studying indigenous healing practices since 2008.
Spring’s workshops, interviews, and writing can be found in mainstream media worldwide.
Highlights:
Key Links:
These show links may contain affiliate links. Third Wave receives a small percentage of the product price if you purchase through the above affiliate links.
Continue the conversation about this episode in Third Wave Community. Create your account for free at community.thethirdwave.co
Episode Sponsors:
In this episode of the Psychedelic Podcast, Paul F. Austin welcomes Christian Angermayer, a serial entrepreneur and investor in psychedelics, longevity, fintech, crypto, and future tech.
Get full show notes, links, and transcript here: https://thethirdwave.co/podcast/episode-207-christian-angermayer/
Christian is a notable figure in the field of psychedelic medicine, both respected and controversial. He has been a driving force in pushing psilocybin toward FDA-approval. But his company atai Life Science's psychedelic patents have drawn criticism from decriminalization-first advocates. Some wonder if the medical approach to psychedelics conflicts with the idea of open access and shamanic usage. Christian delves into this question, examining opposing views and exploring other dichotomies, such as whether capitalism and spirituality can coexist in the realm of psychedelics. He also considers the potential conflict between the search for psychedelic wisdom and the desire for immortality.
Christian’s conversation with Paul presents a new perspective on psychedelics, exploring nuanced topics and questioning the future of psychedelic biotech, microdosing, and longevity science.
Christian Angermayer:
Christian Angermayer is a serial entrepreneur and investor who builds and invests in companies that are shaping the Next Human Agenda: a future in which technology empowers people to live longer, healthier, and happier lives.
Christian’s family office and private investment firm, Apeiron Investment Group, has more than USD 2.5 billion under management and 50 people across five international locations. Apeiron focuses on Life Sciences, FinTech & Crypto, Future Tech and Experiences, and Hospitality & Happiness. Over the past 20 years, Christian has founded three unicorns and has been the lead investor in four unicorns and two decacorns.
Christian is the world’s largest investor in psychedelics and is recognized for leading the current psychedelics renaissance. He founded atai Life Sciences, investigating the potential of psychedelic compounds including psilocybin, ketamine, DMT, and ibogaine as approved medical treatments.
Highlights:
Key Links:
Apeiron Investment Group: https://apeiron-investments.com/
atai Life Sciences: https://atai.life/
COMPASS Pathways: https://compasspathways.com/
Episode Sponsors: